PMID- 34354945
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220425
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 11
DP  - 2021
TI  - Retrospective Study of the Safety and Efficacy of Anlotinib Combined With 
      Dose-Dense Temozolomide in Patients With Recurrent Glioblastoma.
PG  - 687564
LID - 10.3389/fonc.2021.687564 [doi]
LID - 687564
AB  - PURPOSE: The purpose of this study was to retrospectively analyze the safety and 
      clinical efficacy of anlotinib combined with dose-dense temozolomide (TMZ) as the 
      first-line therapy in the treatment of recurrent glioblastoma (rGBM). PATIENTS 
      AND METHODS: We collected the clinical data of 20 patients with rGBM. All 
      patients received anlotinib (12 mg daily, orally for 2 weeks, discontinued for 1 
      week, repeated every 3 weeks) combined with dose-dense TMZ (100 mg/m(2), 7 days 
      on with 7 days off) until the disease progressed (PD) or adverse effects (AEs) 
      above grade 4 appeared. Grade 3 AEs need to be restored to grade 2 before 
      continuing treatment, and the daily dose of anlotinib is reduced to 10 mg. The 
      patients were reexamined by head magnetic resonance imaging (MRI) every 1 to 3 
      months. The therapeutic effect was evaluated according to Response Assessment in 
      Neuro-Oncology (RANO) criteria. The survival rate was analyzed by Kaplan-Meier 
      survival curve analysis. The baseline of all survival index statistics was the 
      start of anlotinib combined with dose-dense of TMZ. National Cancer 
      Institute-Common Terminology Criteria Adverse Events version 4.0 (NCI-CTCAE 4.0) 
      was used to evaluate AEs. RESULTS: Twenty cases of rGBM were evaluated according 
      to the RANO criteria after treatment with anlotinib and dose-dense TMZ, including 
      five cases of stable disease (SD), thirteen cases of partial response (PR), one 
      case of complete response (CR), and one case of PD. The median follow-up time was 
      13.4 (95% CI, 10.5-16.3) months. The 1-year overall survival (OS) rate was 47.7%. 
      The 6-month progression-free survival (PFS) rate was 55%. In the IDH wild type 
      group, the median PFS and median OS were 6.1 and 11.9 months, respectively. We 
      observed that AEs associated with treatment were tolerable. One patient stopped 
      taking the drug because of cerebral infarction. There were no treatment-related 
      deaths. CONCLUSION: Anlotinib combined with dose-dense TMZ for the first-line 
      therapy showed good efficacy in OS, PFS, ORR, and DCR in the treatment of rGBM, 
      and the AEs were tolerant. Randomized controlled clinical trials investigating 
      the treatment of rGBM with anlotinib are necessary.
CI  - Copyright (c) 2021 She, Su, Shen and Liu.
FAU - She, Lei
AU  - She L
AD  - Department of Oncology, Xiangya Hospital, Central South University, Changsha, 
      China.
AD  - Department of Clinical Pharmacology, Xiangya Hospital, Central South University, 
      Changsha, China.
AD  - Institute of Clinical Pharmacology, Central South University, Hunan Key 
      Laboratory of Pharmacogenetics, Changsha, China.
FAU - Su, Lin
AU  - Su L
AD  - Department of Oncology, Xiangya Hospital, Central South University, Changsha, 
      China.
FAU - Shen, Liangfang
AU  - Shen L
AD  - Department of Oncology, Xiangya Hospital, Central South University, Changsha, 
      China.
FAU - Liu, Chao
AU  - Liu C
AD  - Department of Oncology, Xiangya Hospital, Central South University, Changsha, 
      China.
LA  - eng
PT  - Journal Article
DEP - 20210720
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC8330423
OTO - NOTNLM
OT  - adverse events
OT  - anlotinib
OT  - dose-dense temozolomide
OT  - efficacy
OT  - recurrent glioblastoma
OT  - survival
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2021/08/07 06:00
MHDA- 2021/08/07 06:01
PMCR- 2021/07/20
CRDT- 2021/08/06 06:54
PHST- 2021/03/29 00:00 [received]
PHST- 2021/06/30 00:00 [accepted]
PHST- 2021/08/06 06:54 [entrez]
PHST- 2021/08/07 06:00 [pubmed]
PHST- 2021/08/07 06:01 [medline]
PHST- 2021/07/20 00:00 [pmc-release]
AID - 10.3389/fonc.2021.687564 [doi]
PST - epublish
SO  - Front Oncol. 2021 Jul 20;11:687564. doi: 10.3389/fonc.2021.687564. eCollection 
      2021.